Pathologic complete response (pCR) at surgery following neoadjuvant therapy is a strong favorable prognostic biomarker in all subtypes of breast cancer, including HER2+ breast cancer treated with standard modern regimens incorporating HER2-targeted therapy4–6. This evidence concerns the gene ERBB2 and breast carcinoma.